Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEP1B | Q16820 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
| ▸ | SPPL2A | Q8TCT8 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 3/20 | 0.35 |
| ▸ | CTSL | P07711 | 2/20 | 0.35 |
| ▸ | BMP1 | P13497 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5771630 | 0.92 | MEP1B (0.39) | MEP1BALDH1A1ABCB1SPPL2ABACE1 | |
| SCHEMBL4165957 | 0.89 | SPPL2A (0.41) | MEP1BALDH1A1ABCB1SPPL2ABMP1 | |
| SCHEMBL1603109 | 0.86 | SPPL2A (0.43) | ALDH1A1ABCB1SPPL2ALMNA | |
| SCHEMBL1603110 | 0.86 | SPPL2A (0.43) | ALDH1A1ABCB1SPPL2ALMNA | |
| SCHEMBL1601744 | 0.85 | SPPL2A (0.42) | MEP1BALDH1A1ABCB1SPPL2ALMNA | |
| SCHEMBL1601742 | 0.85 | SPPL2A (0.42) | MEP1BALDH1A1ABCB1SPPL2ALMNA | |
| SCHEMBL4351114 | 0.85 | ABCB1 (0.45) | ABCB1SPPL2ABMP1 | |
| SCHEMBL4351110 | 0.85 | ABCB1 (0.45) | ABCB1SPPL2ABMP1 | |
| SCHEMBL12735016 | 0.83 | SPPL2A (0.40) | MEP1BALDH1A1ABCB1SPPL2ABMP1 | |
| SCHEMBL12709319 | 0.83 | SPPL2A (0.40) | MEP1BALDH1A1ABCB1SPPL2ABMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020198388-A1 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED | 2002-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198388-A1 | Inhibitors of aspartyl protease | SPINT2, DNPEP, PRSS1 | MEP1B 2332/4885ALDH1A1 1604/4885ABCB1 628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.